Literature DB >> 8090581

HLA-DR antigen expression in colonic adenomas and adenocarcinomas.

M Teh1, A Wee, G C Raju.   

Abstract

Previous studies have shown that malignant transformation is sometimes associated with the aberrant expression of HLA class II antigens. The functional significance of such aberrant expression is not known. Since HLA-DR antigen is expressed in normal colonic mucosa, it would be interesting to see if malignant transformation could result in the aberrant suppression of this antigen. Sixteen colonic adenocarcinomas, 29 colonic adenomatous polyps and 23 samples of normal colonic mucosa, including 9 cases of colonic mucosa adjacent to carcinoma, were stained immunohistochemically for HLA-DR antigen. The intensity and distribution of the antigen staining in the cytoplasm and luminal surface of the epithelial elements were analysed semiquantitatively. The lymphoplasmacytic infiltrate in the lamina propria was also evaluated. Cytoplasmic HLA-DR antigen expression was found to be significantly diminished in moderately and poorly differentiated adenocarcinomas but not in adenomas or well-differentiated adenocarcinomas. This suggests that the change in HLA-DR expression is not intrinsic to the neoplastic process but may merely be due to the fact that malignant cells, as they become less differentiated, tend to show alterations in their antigenic phenotype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8090581     DOI: 10.1080/00313029400169331

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  2 in total

1.  Identification of differentially expressed genes in normal mucosa, adenoma and adenocarcinoma of colon by SSH.

Authors:  M J Luo; M D Lai
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  Prognostic significance of major histocompatibility complex class II antigens (HLA-DR) in normal colonic mucosa, tubulovillous adenoma, and invasive colonic carcinoma.

Authors:  Demetrio Tamiolakis; Sylvia Nicolaidou; Sophia Bolioti; Anna Tzilivaki
Journal:  Ann Saudi Med       Date:  2006 Mar-Apr       Impact factor: 1.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.